Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin as 1st Line Treatment in Elderly Patients with Advanced Breast Cancer
NCT02404506Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Aug 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Swiss Group for Clinical Cancer Research. Started Aug 2015; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02404506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404506.